

1 **MAJOR ARTICLE**

2 **Immunogenicity of a third dose of BNT162b2 to ancestral SARS-CoV-2 &**  
3 **Omicron variant in adults who received two doses of inactivated vaccine**

4 Nancy H. L. Leung<sup>\*1,2</sup>, Samuel M. S. Cheng<sup>1</sup>, Mario Martín-Sánchez<sup>1</sup>, Niki Y. M. Au<sup>1</sup>, Yvonne  
5 Y. Ng<sup>1</sup>, Leo L. H. Luk<sup>1</sup>, Karl C. K. Chan<sup>1</sup>, John K. C. Li<sup>1</sup>, Yonna W. Y. Leung<sup>1</sup>, Leo C. H.  
6 Tsang<sup>1</sup>, Sara Chaothai<sup>1</sup>, Kelvin K. H. Kwan<sup>1</sup>, Dennis K. M. Ip<sup>1</sup>, Leo L. M. Poon<sup>1,3,4</sup>, Gabriel M.  
7 Leung<sup>1,2</sup>, J. S. Malik Peiris<sup>†1,3,4</sup>, Benjamin J. Cowling<sup>\*†1,2</sup>

8 †Joint senior authors with equal contribution

9

10 **Affiliations:**

11 <sup>1</sup>WHO Collaborating Centre for Infectious Disease Epidemiology and Control, School of Public  
12 Health, LKS Faculty of Medicine, The University of Hong Kong; Hong Kong Special  
13 Administrative Region, China.

14 <sup>2</sup>Laboratory of Data Discovery for Health; Hong Kong Science and Technology Park, Hong  
15 Kong Special Administrative Region, China.

16 <sup>3</sup>HKU-Pasteur Research Pole, School of Public Health, Li Ka Shing Faculty of Medicine, The  
17 University of Hong Kong; Hong Kong Special Administrative Region, China.

18 <sup>4</sup>Centre for Immunology and Infection; Hong Kong Science and Technology Park, Hong Kong  
19 Special Administrative Region, China.

20

21 **Summary: (40 words)**

22 In this open label trial of Chinese adults aged  $\geq 30$  years who received two doses of inactivated  
23 COVID-19 vaccine 6 months earlier, third-dose mRNA vaccine substantially improved antibody  
24 levels against the ancestral virus and Omicron variant with well-tolerated safety profile.

25

26 Word count (abstract): 250

27 Word count (main text): 2,996

28

29 \*Corresponding authors: [bcowling@hku.hk](mailto:bcowling@hku.hk) and [leungnan@hku.hk](mailto:leungnan@hku.hk)

30

31 **ABSTRACT**

32 **Background:** Limited data exist on antibody responses to mixed vaccination strategies involving  
33 inactivated COVID-19 vaccines, particularly in the context of emerging variants.

34 **Methods:** We conducted an open label trial of a third vaccine dose of an mRNA vaccine  
35 (BNT162b2, Fosun Pharma/BioNTech) in adults aged  $\geq 30$  years who had previously received  
36 two doses of inactivated COVID-19 vaccine. We collected blood samples before administering  
37 the third dose and 28 days later, and tested for antibodies to the ancestral virus using a binding  
38 assay (ELISA), a surrogate virus neutralization test (sVNT) and a live virus plaque reduction  
39 neutralization test (PRNT). We also tested for antibodies against the Omicron variant using live-  
40 virus PRNT.

41 **Results:** In 315 participants, a third dose of BNT162b2 substantially increased antibody titers on  
42 each assay. Mean ELISA levels increased from an optical density (OD) of 0.3 to 2.2 ( $p < 0.001$ ),  
43 and mean sVNT levels increased from an inhibition of 17% to 96% ( $p < 0.001$ ). In a random  
44 subset of 20 participants, the geometric mean PRNT<sub>50</sub> titers rose very substantially by at least 24  
45 fold from Day 0 to Day 28 against the ancestral virus ( $p < 0.001$ ) and rose by at least 11 fold  
46 against the Omicron variant ( $p < 0.001$ ). In daily monitoring, post-vaccination reactions subsided  
47 within 7 days for over 99% of participants.

48 **Conclusions:** A third dose of COVID-19 vaccination with an mRNA vaccine substantially  
49 improved antibody levels against the ancestral virus and the Omicron variant with well-tolerated  
50 safety profile, in adults who had received two doses of inactivated vaccine 6 months earlier.

51

52

## 53 INTRODUCTION

54 The accrual of population immunity to COVID-19, acquired through natural infection or  
55 vaccination, will eventually bring an end to the pandemic and allow life to return to normal.  
56 Vaccine technologies being used for COVID-19 include inactivated virus, viral vectored and  
57 mRNA vaccines [1]. We have previously shown that two doses of the mRNA vaccine  
58 BNT162b2 (BioNTech/Fosun Pharma) conferred approximately 10-fold higher post-vaccination  
59 neutralising antibody titers than two doses of the aluminium hydroxide-adjuvanted inactivated  
60 virus vaccine CoronaVac (Sinovac) [2,3], while T cell responses to the two vaccines were similar  
61 [3]. The emergence of variants of concern (VOCs) and decreases in vaccine effectiveness within  
62 a few months after the second vaccine dose have resulted in recommendations for third doses [4].

63  
64 Various studies have reported immunogenicity and safety of third doses using the same vaccine,  
65 i.e. homologous booster vaccination [5,6], but there are few studies evaluating heterologous  
66 booster, such as the use of a third dose of an mRNA vaccine in individuals who previously  
67 received two doses of inactivated vaccine [7-11]. Costa Clemens et al. conducted a non-  
68 inferiority randomised trial of a heterologous third dose of BNT162b2 or other vaccines against a  
69 homologous third dose of CoronaVac in adults who had received two doses of CoronaVac [9].  
70 They showed that all heterologous booster groups have substantial rise in neutralizing antibody  
71 titers (FRNT<sub>50</sub>) against the Omicron and Delta variants [9]. They also reported more local  
72 reactions but less systemic reactions to BNT162b2 compared to two adenoviral vectored  
73 vaccines given as third doses. Pérez-Then et al. reported a third dose of BNT162b2 vaccination  
74 conferred a 1.4-fold increase in neutralizing antibodies (PRNT<sub>50</sub>) against Omicron when  
75 compared to two doses of an mRNA vaccine (BNT162b2 or mRNA-1273) [8]. Here, we report a

76 trial of the immunogenicity and reactogenicity to a third dose of BNT162b2 in Chinese adults  
77 who had previously received two doses of inactivated COVID-19 vaccine.

78

## 79 **MATERIALS AND METHODS**

### 80 **Study design**

81 The “mRNA vaccination to boost antibodies against SARS-CoV-2 in recipients of inactivated  
82 vaccines” (mBoost) study is an open-label single-arm clinical trial to measure the antibody  
83 responses and reactogenicity of an mRNA vaccine (BNT162b2) given as a third dose in adults  
84  $\geq 30$  years of age who have previously received two doses of an inactivated COVID-19 vaccine.  
85 CoronaVac and BNT162b2 have been available to adults in Hong Kong since March 2021. Some  
86 Hong Kong residents could have received two doses of inactivated vaccine BIBP (Sinopharm)  
87 instead from mainland China or overseas. The BNT162b2 vaccine used in Hong Kong, known as  
88 the Pfizer/BioNTech vaccine elsewhere, are distributed solely by Fosun Pharma in Greater  
89 China.

90

91 Enrolment invitations were extended to community-dwelling adults in Hong Kong through mass  
92 promotion efforts including advertisements in newspapers and social media. Interested adults  
93 were invited to visit the study website and complete an online screening form for initial  
94 assessment of enrolment eligibility, and confirmed again shortly before vaccination. Individuals  
95 were eligible if they were aged  $\geq 30$  years, had previously received two doses of an inactivated  
96 COVID-19 vaccine with the most recent dose  $\geq 90$  days prior to enrolment. We excluded  
97 individuals who reported a history of COVID-19 infection, received any dose of COVID-19  
98 vaccine other than an inactivated vaccine, or who were unsuitable to receive an mRNA vaccine

99 including but not limited to allergies to the active substance or other ingredients of the vaccine.  
100 We also excluded individuals with diagnosed medical conditions related to their immune system,  
101 use of medication that impairs immune system in the last 6 months except topical steroids or  
102 short-term oral steroids (course lasting  $\leq 14$  days), those who had used immunoglobulins or any  
103 blood products within 90 days prior to enrolment, and any females who were pregnant or  
104 intending to become pregnant in the coming 3 months.

105

106 We collected 20ml clotted blood specimens at the day of enrolment and vaccination (day 0) and  
107 again after 28 days, with additional blood draws planned after 182 and 365 days. This was a  
108 single-arm study with no need for randomization, and the participants and the study staff were  
109 aware of the type of vaccination administered (no blinding). After vaccination, participants were  
110 observed for 30 minutes to record any immediate events. We then asked participants to report the  
111 presence of a list of (post-vaccination) local or systematic events/reactions daily for 7 days using  
112 an online e-diary. If the participant was still reporting any events/reaction on Day 7, additional  
113 daily monitoring continued for up to three additional weeks until symptoms resolved. On each  
114 day, participants were also asked to grade whether the reported symptoms overall have interfered  
115 with their usual activities (mild, moderate and severe). Participants are interviewed at 28, 182  
116 and 365 days after vaccination to collect information on underlying medical conditions, and any  
117 medical encounters including hospitalizations during the study. Participants were provided with a  
118 free tympanic thermometer at enrolment, and a gift voucher of HK\$100 (US\$13) at the follow-  
119 up blood draws. Study data were collected and managed using REDCap electronic data capture  
120 tools [12,13].

121

122 **Ethics**

123 Written informed consent was obtained from all participants. The study protocol was approved  
124 by the Institutional Review Board of the University of Hong Kong. The study was registered on  
125 Clinicaltrials.gov prior to commencement (NCT05057182).

126

127 **Outcome measures**

128 The primary outcome measure is the vaccine immunogenicity at 28 days after receipt of the third  
129 dose of BNT162b2, measured as geometric mean titer (GMT) of SARS-CoV-2 serum  
130 neutralizing antibodies against the vaccine strain (i.e. the ancestral virus) using plaque reduction  
131 neutralization test (PRNT). As the Omicron strain emerged in late 2021, we also evaluated  
132 vaccine immunogenicity against the Omicron strain. The secondary outcome measures include  
133 the GMT at other post-vaccination timepoints (i.e. at days 182 and 365) and mean-fold rises in  
134 antibody titers from baseline to each post-vaccination timepoint, and the incidence of solicited  
135 reactions or medical encounters following vaccination.

136

137 **Sample size justification**

138 For the primary outcome of vaccine immunogenicity, i.e. the GMT of SARS-CoV-2 serum  
139 neutralizing antibodies against the vaccine strain (ancestral virus) at 28 days after vaccination, a  
140 sample size of 300 individuals was chosen based of feasibility [14].

141

142 **Laboratory methods**

143 Blood samples were delivered to our study laboratory at the University of Hong Kong as soon as  
144 possible, with the optimal delivery time within 24h. Sera were extracted from the clotted blood

145 within 48h and stored at -80°C until subsequent testing. We tested sera heat inactivated at 56°C  
146 for 30 minutes with three assays, our in-house enzyme-linked immunosorbent assay (ELISA) for  
147 the receptor binding domain (RBD) of the spike protein, a surrogate virus neutralisation test  
148 (sVNT) (GenScript), and a plaque reduction neutralisation test (PRNT) as previously described  
149 [11,15,16]. We aimed to tested sera collected at baseline and Day 28 with the ELISA and sVNT  
150 in all participants, and with PRNT in a randomly-selected subset of 20 participants. We have  
151 demonstrated a good correlation ( $r=0.77$ ) between PRNT<sub>50</sub> and sVNT neutralization percentage  
152 for ancestral virus in our earlier studies [17]. The ELISA was not designed as a quantitative  
153 assay, although it has a dynamic range of between 0 to 5 and we have demonstrated a good  
154 correlation ( $r=0.83$ ) between ELISA OD<sub>450</sub> and sVNT neutralization percentage for ancestral  
155 virus [17]. For ELISA a single 1:100 and for sVNT a single 1:10 serum dilution was tested  
156 respectively. For PRNT, a serial two-fold serum dilutions from 1:10 to 1:320 were tested. PRNT  
157 assays were carried out using ancestral SARS-CoV-2 BetaCoV/Hong Kong/VM20001061/2020  
158 isolated in Hong Kong in January 2020 in Vero-E6 cells (ATCC CRL-1586), the Pango lineage  
159 B.1.1.529 Omicron variant designated hCoV-19/Hong Kong/VM21044713\_WHP5047-S5/2021  
160 isolated in Vero-E6 TMRSS2 cells (Vero E6 cells overexpressing TMRSS2, kindly provided by  
161 Dr S Matsuyama and colleagues), and the passage level 3 virus aliquots were used. Cells were  
162 maintained in DMEM medium supplemented with 10% FBS and 100 U/ml penicillin–  
163 streptomycin (all from ThermoFisher Scientific, Waltham, MA, USA). Virus sequences are  
164 available in GISAID as EPI\_ISL\_412028 and EPI\_ISL\_6716902. The PRNT<sub>50</sub> and PRNT<sub>90</sub> titers  
165 were the highest serum dilutions neutralizing  $\geq 50\%$  and  $\geq 90\%$  of input plaques, respectively.  
166 The WHO control serum provided by the National Institute for Biological Standards and Control



167 20/136 gave PRNT<sub>50</sub> titers of 320 and 320 against the ancestral virus and 20 and 40 against the  
168 Omicron variant in two titrations [11].

169

## 170 **Statistical analysis**

171 We assessed the GMT of SARS-CoV-2 (PRNT) neutralizing antibody titers, surrogate virus  
172 neutralization percentages and the mean concentrations of SARS-CoV-2 Spike RBD IgG (proxy  
173 by OD<sub>450</sub>) at Day 28. For sVNT, measured negative neutralization percentages were transformed  
174 to zero. PRNT titers were taken as the reciprocal of the serum dilution and were interval-  
175 censored, e.g. a sample that was able to neutralise virus at a 1:20 dilution but not at a 1:40  
176 dilution was reported as 20 to indicate that the titer was  $\geq 20$  and  $< 40$ . We imputed titers  $< 10$  with  
177 the value 5 and titers  $\geq 320$  with the value 640 for estimation of GMTs. We compared antibody  
178 levels at Day 28 after receipt of BNT162b2 to baseline using Wilcoxon signed rank tests.  
179 Correlation of PRNT<sub>90</sub> titers measured at Day 28 against the ancestral strain and the Omicron  
180 variant was estimated by Spearman's rank correlation coefficient. Reactogenicity endpoints were  
181 described as frequency (%) for local and systemic reactions or events among participants who  
182 reported health status for at least one day in the week following receipt of the third dose of  
183 BNT162b2. Statistical analyses were conducted using R version 4.1.2.

184

## 185 **RESULTS**

186 From 13 October 2021 through 18 January 2022 we screened 436 individuals, of which 366  
187 (84%) were eligible and 315 (86%) were enrolled and administered BNT162b2 vaccination. We  
188 collected paired Day 0 and Day 28 blood samples in 312 (99%) vaccinated participants. Most of  
189 the participants were older Chinese adults (median aged 54 years, IQR 47-62), with 35% who

190 were obese, and about one-third reported at least one chronic medical condition including  
191 hypertension (18%), hypercholesterolemia (13%) and diabetes (7%), and almost all (98%)  
192 reported receiving two doses of CoronaVac rather than other inactivated vaccines (Table 1).  
193 Although adults who had received two doses of inactivated virus vaccination at least 90 days ago  
194 were eligible to enrol into our study (Figure S1), 75% of participants reported receiving the  
195 second dose typically around 6-7 months earlier (Table 1). A detailed flow chart of participant  
196 enrolment is provided in Figure S1. The study is ongoing and Day 182 and 365 samples will be  
197 collected in Spring 2022 and Autumn 2022 respectively.

198  
199 The third dose of BNT162b2 substantially increased antibody titers measured by the various  
200 assays (Figure 1). Mean ELISA levels increased from a OD of 0.3 to 2.2 ( $p < 0.001$ ), and mean  
201 sVNT levels increased from an inhibition of 17% to 96% ( $p < 0.001$ ) (Table 2). We randomly  
202 selected a subset of 20 participants for further PRNT testing against the ancestral virus and the  
203 Omicron strain (Table 1). The ELISA and sVNT levels in these 20 participants were similar to  
204 that of the 312 vaccinated participants (Figure S2). In these 20 participants, the geometric mean  
205 PRNT<sub>50</sub> titer against the ancestral strain at Day 0 was 12. We could not estimate the GMT at Day  
206 28 because 18/20 (90%) samples were positive at the highest dilution of 1:320, and we noted that  
207 if the GMT were  $\geq 320$  it would correspond to a mean-fold titer rise of  $\geq 24$  from Day 0 to Day 28  
208 ( $p < 0.001$ ). The geometric mean PRNT<sub>90</sub> titer against the ancestral strain at Day 0 was 6. At Day  
209 28, 12/20 samples were positive at the highest dilution of 1:320, and we noted that if the GMT  
210 were  $\geq 320$  it would correspond to a mean-fold titer rise of  $\geq 35$  in PRNT<sub>90</sub> titers from Day 0 to  
211 Day 28 ( $p < 0.001$ ). Furthermore, in these same 20 participants the geometric mean PRNT<sub>50</sub> titer  
212 against the Omicron strain at Day 0 was 5, and rose to 59 at Day 28, a mean-fold rise of at least

213 11 given that the Day 0 titers were almost all assigned values of 5 corresponding to the floor of  
214 the assay at <10 ( $p<0.001$ ). The geometric mean PRNT<sub>90</sub> titer against the Omicron strain at Day  
215 0 was also 5, and rose to 19 at Day 28, a mean-fold rise of at least 3 ( $p<0.001$ ). We did not  
216 identify any evidence that suggest a correlation between the PRNT<sub>90</sub> titers against the Omicron  
217 variant and that against the ancestral virus ( $r=0.30$ ,  $p=0.21$ ) (Figure S3).

218  
219 Among the 315 participants who received BNT162b2 vaccination, 304 (97%) participants  
220 reported health status for at least one day in the week following receipt of BNT162b2, including  
221 234 (77%) who reported every day and another 38 (13%) reported for  $\geq 7$  days. 193/304 (63%)  
222 participants reported feeling unwell for an average of 2.9 days (SD 1.8 days), and only 3 (<1%)  
223 participants reported feeling unwell beyond 7 days after third-dose BNT162b2 vaccination.

224 Within the 7 days after receipt of BNT162b2, the most commonly reported local reactions were  
225 pain (46%) and tenderness (44%) at the injection site, while systemic reactions were reported by  
226 a minority of participants (Table 3). These symptoms usually subsided within 7 days after  
227 vaccination (Figure 2). Among 312 participants whose information is available, 6 (2%) reported  
228 having sought medical consultation within one month of the third dose but none were  
229 hospitalized. Among these 6 participants, 4 reported seeking medical consultation possibly for  
230 discomfort associated with vaccination within the week after vaccination, and the remaining two  
231 participants sought medical consultation due to back pain or stress outside the 7-day window.

232

## 233 **DISCUSSION**

234 Work by our research group and others indicates that two doses of inactivated COVID-19  
235 vaccine confer moderate increases in antibody levels at one month after the second dose [2, 3].

236 Antibody levels then gradually decline, but can be boosted by receipt of third doses. Zeng et al.  
237 reported that a third dose of inactivated vaccine given to healthy young adults at 8 months after  
238 the second dose of the same vaccine boosted neutralizing antibodies against the ancestral strain  
239 by about 21-fold [5]. Here, we show that a third dose of mRNA vaccine (BNT162b2) after two  
240 doses of inactivated virus vaccine (mostly CoronaVac), all originally formulated against the  
241 ancestral virus, boosted PRNT<sub>50</sub> titers against the ancestral strain by a factor of at least 27-fold.  
242 Similarly, Clemens et al. showed that a third dose of mRNA or adenoviral vectored vaccines  
243 induced greater rises in anti-Spike binding antibodies compared to a third dose of inactivated  
244 vaccine among CoronaVac recipients [9]. Both suggest a substantial improvement of  
245 heterologous boosting using mRNA vaccine over homologous boosting using inactivated vaccine  
246 against the ancestral virus. We also show that a third dose of BNT162b2 conferred substantial  
247 rises in PRNT<sub>50</sub> titers against the Omicron variant. While there is still a lack of consensus on the  
248 antibody threshold for protection [18-21], the PRNT<sub>50</sub> titers against Omicron at Day 28 in our  
249 study are higher than the PRNT<sub>50</sub> titers against ancestral virus after two doses of CoronaVac  
250 where the geometric mean PRNT<sub>50</sub> titer was estimated to be 27 [2]. Given that two doses of  
251 inactivated vaccine were estimated to provide at least 50% protection against infection with the  
252 ancestral virus [22-24], the antibody levels against Omicron estimated in our study could  
253 correspond to a moderate degree of effectiveness in protection against Omicron.  
254  
255 Most of the participants in our study were older adults, and their antibody levels against Omicron  
256 were at a very low level at Day 0 prior to the third dose, consistent with other recent studies  
257 [8,9]. Almost one-third of participants had underlying medical conditions (Table 1). In our  
258 separate initial investigation which included sera from individuals with various intervals (51-234

259 days) between second and third dose [11] and some of whom were selected for third dose  
260 vaccination due to low (<60%) post-second dose serum surrogate neutralizing antibodies [25],  
261 we showed that administering BNT162b2 about 3 months after two doses of CoronaVac reported  
262 a GMT of 59 against Omicron compared to 305 against the ancestral virus after the boost [11].  
263 Costa Clemens et al. showed that heterologous boosting with third dose of mRNA or adenoviral  
264 vectored vaccines induced greater rise in neutralising antibodies against both Omicron and Delta  
265 variants than homologous boosting with inactivated vaccines [9]. Together, these studies suggest  
266 the substantial boost in neutralizing antibody titers against both the ancestral virus and Omicron  
267 variant by a heterologous third dose of mRNA vaccination will clearly improve protection  
268 against the Omicron strain (and potentially other variant strains).

269  
270 Earlier studies have investigated post-vaccination reactions after two or three doses of  
271 inactivated [5, 23, 26] or mRNA vaccination [27,28]. These studies suggest fatigue, myalgia and  
272 chill were common both after receipt of inactivated [23] or mRNA vaccines [27]; nausea was  
273 common after inactivated vaccination [23]; and fever and headache after mRNA vaccination  
274 [27]. Similar to reactions after mRNA vaccination, feverishness and headache were commonly  
275 reported in our study while gastrointestinal symptoms such as nausea and diarrhoea were less  
276 commonly reported. No hospitalization was reported within the month after vaccination in our  
277 study, although our sample size would not have been large enough to detect rare events.

278  
279 Our study had several limitations. We have only performed PRNT against ancestral strain and  
280 Omicron variant up to a dilution of 1:320. However, more than half of our study participants  
281 were positive for antibodies to the ancestral strain at this dilution indicating antibody titers  $\geq 320$ ,

282 and we were therefore not able to determine exactly the GMT against ancestral strain after the  
283 third dose of vaccination but only confirm that it was likely  $\geq 320$ . Similarly, Day 0 samples were  
284 typically negative even at the starting dilution of 1:10, limiting our assessment of pre-vaccination  
285 GMTs. Nevertheless, we were able to conclude that third dose of mRNA vaccination would  
286 provide substantial benefits against both ancestral and Omicron strains. Our results on  
287 immunogenicity may be subjected to selection bias including volunteer bias, since in Hong Kong  
288 older adults are more inclined to receive the inactivated vaccines and younger adults to mRNA  
289 vaccines [29]. Our results on reactogenicity may be subjected to information bias as this was an  
290 open-label trial and it is recognized that there could be more post-vaccination reactions after  
291 mRNA vaccination compared to inactivated vaccination [30].

292

293

294 **References**

- 295 1. Subbarao K. The success of SARS-CoV-2 vaccines and challenges ahead. *Cell Host*  
296 *Microbe* **2021**; 29(7): 1111-23.
- 297 2. Lim WW, Mak L, Leung GM, Cowling BJ, Peiris M. Comparative immunogenicity of  
298 mRNA and inactivated vaccines against COVID-19. *Lancet Microbe* **2021**; 2(9): e423.
- 299 3. Mok CKP, Cohen CA, Cheng SMS, et al. Comparison of the immunogenicity of  
300 BNT162b2 and CoronaVac COVID-19 vaccines in Hong Kong. *Respirology* **2022**;  
301 27(4): 301-10.
- 302 4. Bar-On YM, Goldberg Y, Mandel M, et al. Protection of BNT162b2 Vaccine Booster  
303 against Covid-19 in Israel. *N Engl J Med* **2021**; 385(15): 1393-400.
- 304 5. Zeng G, Wu Q, Pan H, et al. Immunogenicity and safety of a third dose of CoronaVac,  
305 and immune persistence of a two-dose schedule, in healthy adults: interim results from  
306 two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials.  
307 *Lancet Infect Dis* **2022**; 22(4): 483-95.
- 308 6. Falsey AR, Frenck RW, Jr., Walsh EE, et al. SARS-CoV-2 Neutralization with  
309 BNT162b2 Vaccine Dose 3. *N Engl J Med* **2021**; 385(17): 1627-9.
- 310 7. Intapiboon P, Seepathomnarong P, Ongarj J, et al. Immunogenicity and Safety of an  
311 Intradermal BNT162b2 mRNA Vaccine Booster after Two Doses of Inactivated SARS-  
312 CoV-2 Vaccine in Healthy Population. *Vaccines (Basel)* **2021**; 9(12): 1375.
- 313 8. Perez-Then E, Lucas C, Monteiro VS, et al. Neutralizing antibodies against the SARS-  
314 CoV-2 Delta and Omicron variants following heterologous CoronaVac plus BNT162b2  
315 booster vaccination. *Nat Med* **2022**; 28(3): 481-5.

- 316 9. Costa Clemens SA, Weckx L, Clemens R, et al. Heterologous versus homologous  
317 COVID-19 booster vaccination in previous recipients of two doses of CoronaVac  
318 COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind,  
319 randomised study. *Lancet* **2022**; 399(10324): 521-9.
- 320 10. Munro APS, Janani L, Cornelius V, et al. Safety and immunogenicity of seven COVID-  
321 19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or  
322 BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled,  
323 phase 2 trial. *Lancet* **2021**; 398(10318): 2258-76.
- 324 11. Cheng SMS, Mok CKP, Leung YWY, et al. Neutralizing antibodies against the SARS-  
325 CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or  
326 BNT162b2 vaccination. *Nat Med* **2022**; 28(3): 486-9.
- 327 12. Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic  
328 data capture (REDCap)--a metadata-driven methodology and workflow process for  
329 providing translational research informatics support. *J Biomed Inform* **2009**; 42(2): 377-  
330 81.
- 331 13. Harris PA, Taylor R, Minor BL, et al. The REDCap consortium: Building an  
332 international community of software platform partners. *J Biomed Inform* **2019**; 95:  
333 103208.
- 334 14. World Health Organization. Guidelines on clinical evaluation of vaccines: regulatory  
335 expectations. Geneva, Switzerland, **2017**.
- 336 15. Perera RA, Mok CK, Tsang OT, et al. Serological assays for severe acute respiratory  
337 syndrome coronavirus 2 (SARS-CoV-2), March 2020. *Euro Surveill* **2020**; 25(16).



- 338 16. Perera R, Ko R, Tsang OTY, et al. Evaluation of a SARS-CoV-2 Surrogate Virus  
339 Neutralization Test for Detection of Antibody in Human, Canine, Cat, and Hamster Sera.  
340 J Clin Microbiol **2021**; 59(2).
- 341 17. Lau EH, Hui DS, Tsang OT, et al. Long-term persistence of SARS-CoV-2 neutralizing  
342 antibody responses after infection and estimates of the duration of protection.  
343 EClinicalMedicine **2021**; 41: 101174.
- 344 18. Earle KA, Ambrosino DM, Fiore-Gartland A, et al. Evidence for antibody as a protective  
345 correlate for COVID-19 vaccines. Vaccine **2021**; 39(32): 4423-8.
- 346 19. Feng S, Phillips DJ, White T, et al. Correlates of protection against symptomatic and  
347 asymptomatic SARS-CoV-2 infection. Nat Med **2021**; 27(11): 2032-40.
- 348 20. Gilbert PB, Montefiori DC, McDermott AB, et al. Immune correlates analysis of the  
349 mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science **2022**; 375(6576): 43-50.
- 350 21. Khoury DS, Cromer D, Reynaldi A, et al. Neutralizing antibody levels are highly  
351 predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med  
352 **2021**; 27(7): 1205-11.
- 353 22. Al Kaabi N, Zhang Y, Xia S, et al. Effect of 2 Inactivated SARS-CoV-2 Vaccines on  
354 Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial. JAMA **2021**;  
355 326(1): 35-45.
- 356 23. Tanriover MD, Doganay HL, Akova M, et al. Efficacy and safety of an inactivated  
357 whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind,  
358 randomised, placebo-controlled, phase 3 trial in Turkey. Lancet **2021**; 398(10296): 213-  
359 22.

- 360 24. Kim JH, Marks F, Clemens JD. Looking beyond COVID-19 vaccine phase 3 trials. *Nat*  
361 *Med* **2021**; 27(2): 205-11.
- 362 25. Mok CKP, Cheng SMS, Chen C, et al. A RCT Using CoronaVac or BNT162b2 Vaccine  
363 as a Third Dose in Adults Vaccinated with Two Doses of CoronaVac. *Am J Respir Crit*  
364 *Care Med* **2022**.
- 365 26. Cao Y, Hao X, Wang X, et al. Humoral immunogenicity and reactogenicity of  
366 CoronaVac or ZF2001 booster after two doses of inactivated vaccine. *Cell Res* **2022**;  
367 32(1): 107-9.
- 368 27. Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA  
369 Covid-19 Vaccine. *N Engl J Med* **2020**; 383(27): 2603-15.
- 370 28. Choi A, Koch M, Wu K, et al. Safety and immunogenicity of SARS-CoV-2 variant  
371 mRNA vaccine boosters in healthy adults: an interim analysis. *Nat Med* **2021**; 27(11):  
372 2025-31.
- 373 29. McMenamin ME, Nealon J, Lin Y, et al. Vaccine effectiveness of two and three doses of  
374 BNT162b2 and CoronaVac against COVID-19 in Hong Kong. [Preprint]. Available  
375 from: <https://www.medrxiv.org/content/10.1101/2022.03.22.22272769v2>.
- 376 30. McDonald I, Murray SM, Reynolds CJ, Altmann DM, Boyton RJ. Comparative  
377 systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of  
378 vaccines against SARS-CoV-2. *NPJ Vaccines* **2021**; 6(1): 74.

379

380

381 **Acknowledgements**

382 We gratefully acknowledge colleagues including Eileen Yu, Teresa So and Zacary Chai for  
383 technical support in preparing and conducting this study; Anson Ho for setting up the database;  
384 Julie Au and Lilly Wang for administrative support; Hetti Cheung, Victoria Wong, Bobo Yeung  
385 at HKU Health System; Cindy Man and other colleagues at the HKU Community Vaccination  
386 Centres at Gleneagles Hospital; and all the study participants for facilitating the study.

387

388 **Funding**

389 This project was supported by the Theme-based Research Scheme T11-712/19-N of the Research  
390 Grants Council of the Hong Kong Special Administrative Region, China (BJC). BJC is  
391 supported by a RGC Senior Research Fellow Scheme grant (HKU SRFS2021-7S03) from the  
392 Research Grants Council of the Hong Kong Special Administrative Region, China. The funding  
393 bodies had no role in the design of the study, the collection, analysis, and interpretation of data,  
394 or writing of the manuscript.

395

396 **Author contributions**

397 All authors meet the ICMJE criteria for authorship. Each author's contributions to the paper are  
398 listed below according to the CRediT model:

399 Conceptualization: NHLL, GML, BJC

400 Methodology: NHLL, SMSC

401 Formal analysis: NHLL, MM-S

402 Investigation: NYMA, YYN, LLHL, KCKC, JKCL, YWYL, LCHT, SC, KKHK

403 Funding acquisition: BJC

404 Project administration: NHLL, SMSC, JSMP, BJC

405 Supervision: NHLL, SMSC, DKMI, LLMP, GML, JSMP, BJC

406 Writing – original draft: NHLL, MM-S, JSMP, BJC

407 Writing – review & editing: NHLL, SMSC, MM-S, NYMA, YYN, LLHL, KCKC, JKCL,

408 YWYL, LCHT, SC, KKHK, DKMI, LLMP, GML, JSMP, BJC.

409

410 **Competing interests**

411 BJC consults for AstraZeneca, Fosun Pharma, GlaxoSmithKline, Moderna, Pfizer, Roche and

412 Sanofi Pasteur. BJC has received research funding from Fosun Pharma. The authors report no

413 other potential conflicts of interest.

414

415

416

417 **FIGURE LEGENDS**

418 **Figure 1. Third dose of SARS-CoV-2 BNT162b2 vaccine boosts serum antibodies against**  
419 **ancestral strain and Omicron variant in adults who previously received two doses of**  
420 **inactivated vaccines. (A)** ELISA for serum IgG against SARS-CoV-2 Spike receptor binding  
421 domain (RBD) of ancestral strain. **(B)** Surrogate virus neutralization test (sVNT) against  
422 ancestral strain. Live virus plaque reduction neutralization test (PRNT) against ancestral strain  
423 with endpoints at **(C)** 50% (PRNT<sub>50</sub>) or **(D)** 90% (PRNT<sub>90</sub>). Live virus plaque reduction  
424 neutralization test (PRNT) against Omicron variant with endpoints at **(E)** 50% (PRNT<sub>50</sub>) or **(F)**  
425 90% (PRNT<sub>90</sub>). X in each panel indicates the median level. Data for ELISA and sVNT were  
426 available from 312 vaccinated participants whom paired day 0 and day 28 sera were collected,  
427 while data for PRNT were available from a random sample of 20 participants.

428

429 **Figure 2. Solicited local and systemic reactions during the 7 days after third dose**  
430 **BNT162b2 vaccination in adults who previously received two doses of inactivated COVID-**  
431 **19 vaccine.** \*For solicited systemic reactions, only feverish/fever  $\geq 38.0^{\circ}\text{C}$ / chills, and those  
432 reported in at least 10% of participants are shown.

433

434 **Figure S1. Flow chart for this single-arm, open-label clinical trial of BNT162b2 provided as**  
435 **a third vaccine dose in adults who previously received two doses of inactivated COVID-19**  
436 **vaccine.**

437

438

439

440 **Figure S2. ELISA and sVNT antibody levels in 20 participants randomly selected to be**  
441 **tested by PRNT compared to all vaccinated participants with paired Day 0 and Day 28 sera**  
442 **collected. (A)** ELISA for serum IgG against SARS-CoV-2 Spike receptor binding domain  
443 (RBD) of ancestral strain. **(B)** Surrogate virus neutralization test (sVNT) against ancestral strain.  
444 X indicates the mean level. All: all vaccinated participants with paired Day 0/ Day 28 sera  
445 collected (N = 312); Selected: participants randomly selected to be tested by PRNT (N = 20).

446  
447 **Figure S3. Correlation of PRNT<sub>90</sub> titers measured at Day 28 against ancestral strain and**  
448 **the Omicron variant in 20 participants randomly selected for performing PRNT. PRNT**  
449 **titers are measured based on two-fold dilutions and plotted here within an interval, or <10**  
450 **(plotted on axis) or  $\geq 320$  (plotted above 320). r: Spearman's rank correlation coefficient; p: p-**  
451 **value.**

452

453

454 **Table 1. Characteristics of study participants at baseline.** We enrolled and administered  
 455 BNT162b2 vaccine as a third vaccine dose in 315 adults who previously received two doses of  
 456 inactivated COVID-19 vaccine. Among them, ELISA and sVNT against ancestral SARS-CoV-2  
 457 virus were performed in paired Day 0 and Day 28 sera available from 312 vaccinated  
 458 participants, and we randomly selected 20 participants to also perform PRNT against ancestral  
 459 SARS-CoV-2 virus and the Omicron variant. ELISA: enzyme-linked immunosorbent assay;  
 460 sVNT: surrogate virus neutralisation test; PRNT: plaque reduction neutralisation test.  
 461

Characteristic	Participants tested by ELISA & sVNT	Random subset of 20 participants tested by ELISA, sVNT & PRNT
	(N = 312)	(N = 20)
	n (%)	n (%)
<b>Female</b>	120 (38)	9 (45)
<b>Age (median, IQR)</b>	54 (47-62)	55 (47-64)
<b>Ethnicity</b>		
Chinese	306 (98)	20 (100)
<b>Obesity (for Asian populations)</b>		
Underweight (BMI < 18.5)	6 (2)	0 (0)
Normal (BMI 18.5 – 22.9)	114 (37)	5 (25)
Overweight (BMI 23.0 – 24.9)	84 (27)	7 (35)
Obese (BMI ≥ 25.0)	108 (35)	8 (40)
<b>Chronic medical conditions</b>		
Any	98 (32)	6 (30)
Lung disease, including COPD and asthma	1 (0)	0 (0)
Heart disease	7 (2)	0 (0)
Hypertension	57 (18)	5 (25)
Diabetes	22 (7)	1 (5)
Hypercholesterolemia	42 (13)	3 (15)
Kidney disease	4 (1)	0 (0)
Liver disease	4 (1)	1 (5)
Cancer	5 (2)	1 (5)
<b>Prior COVID-19 vaccination</b>		
2-dose CoronaVac (Sinovac)	305 (98)	20 (100)
2-dose BIBP (Sinopharm)	7 (2)	0 (0)
<b>Days between first and second dose of COVID-19 vaccination (median, IQR)</b>	28 (28-29)	28 (28-29)
<b>Days between second and third (study) dose of</b>	206 (192-217)	197 (172-208)

**COVID-19 vaccination (median, IQR)**

**Smoking**

Ever	33 (11)	5 (25)
Current	22 (7)	3 (15)

---

462

463

464

465

466

467



468 **Table 2. Antibody response after third dose BNT162b2 vaccination in adults who**  
 469 **previously received two doses of inactivated COVID-19 vaccine.** ELISA and sVNT against  
 470 ancestral SARS-CoV-2 virus were performed in paired Day 0 and Day 28 sera available from  
 471 312 vaccinated participants, and we randomly selected 20 participants to also perform PRNT  
 472 against ancestral SARS-CoV-2 virus and the Omicron variant. Significant differences between  
 473 antibody level at Day 0 and Day 28 was evaluated by Wilcoxon signed rank tests. ELISA:  
 474 enzyme-linked immunosorbent assay; sVNT: surrogate virus neutralisation test; PRNT: plaque  
 475 reduction neutralisation test; GMT: geometric mean titer.  
 476

	Participants tested by ELISA & sVNT (N = 312)			Participants tested by ELISA, sVNT & PRNT (N = 20)		
	Day 0	Day 28	p-value	Day 0	Day 28	p-value
<b>Ancestral ELISA</b>						
Mean (SD)	0.3 (0.2)	2.2 (0.4)	<0.001	0.3 (0.3)	2.0 (0.3)	<0.001
Median (IQR)	0.2 (0.2-0.4)	2.0 (1.9-2.5)		0.2 (0.2-0.3)	1.9 (1.8-2.0)	
<b>Ancestral sVNT</b>						
Mean (SD)	17% (16)	96% (3)	<0.001	21% (16)	97% (1)	<0.001
Median (IQR)	13% (5-23)	97% (96-97)		21% (6-32)	97% (97-97)	
<b>Ancestral PRNT<sub>50</sub></b>						
GMT (SD)				12 (2)	557 (2)	<0.001
Median (IQR)		N/A		10 (5-20)	≥320 (≥320-≥320)	
<b>Ancestral PRNT<sub>90</sub></b>						
GMT (SD)				6 (1)	309 (3)	<0.001
Median (IQR)		N/A		5 (5-5)	≥320 (160-≥320)	
<b>Omicron PRNT<sub>50</sub></b>						
GMT (SD)				5 (1)	59 (4)	<0.001
Median (IQR)		N/A		5 (5-5)	40 (20-100)	
<b>Omicron PRNT<sub>90</sub></b>						
GMT (SD)				5 (1)	19 (3)	<0.001
Median (IQR)		N/A		5 (5-5)	15 (10-40)	

477 Footnote: For the estimation of GMT for PRNT<sub>50</sub> and PRNT<sub>90</sub> titers, titers <10 were imputed as 5 and titers  
 478 ≥320 were imputed as 640.

479 **Table 3. Solicited local and systemic reactions on the day after and anytime within 7 days**  
 480 **after third dose BNT162b2 vaccination in adults who previously received two doses of**  
 481 **inactivated COVID-19 vaccine.** Daily frequencies within 7 days after third dose BNT162b2  
 482 vaccination for reactions highlighted in bold are shown in Figure 2.  
 483

Post-vaccination reactions	Anytime within 7 days after third	Day 1 after third dose BNT162b2
	dose BNT162b2 vaccination (N = 304) n (%)	vaccination (N = 304) n (%)
<b><u>Local reactions at the injection site</u></b>		
<b>Pain*</b>	<b>141 (46)</b>	<b>130 (43)</b>
<b>Tenderness*</b>	<b>133 (44)</b>	<b>108 (36)</b>
<b>Swelling or hardness*</b>	<b>71 (23)</b>	<b>51 (17)</b>
<b>Itchiness*</b>	<b>20 (7)</b>	<b>2 (1)</b>
<b>Redness*</b>	<b>15 (5)</b>	<b>5 (2)</b>
<b><u>Systemic reactions and general symptoms</u></b>		
<b>Feverish</b>	<b>72 (24)</b>	<b>55 (18)</b>
<b>Fever <math>\geq 38.0^{\circ}\text{C}</math></b>	<b>26 (9)</b>	<b>20 (7)</b>
<b>Chills</b>	<b>32 (11)</b>	<b>29 (10)</b>
<b>Headache</b>	<b>75 (25)</b>	<b>56 (18)</b>
<b>Myalgia</b>	<b>54 (18)</b>	<b>38 (12)</b>
<b>Fatigue</b>	<b>56 (18)</b>	<b>42 (14)</b>
<b>Drowsiness</b>	<b>51 (17)</b>	<b>38 (12)</b>
<b>Malaise</b>	<b>31 (10)</b>	<b>20 (7)</b>
Pain at the injection arm	25 (8)	14 (5)
Loss of appetite	21 (7)	12 (4)
Dizziness	21 (7)	11 (4)
Runny nose	20 (7)	12 (4)
Nasal congestion	19 (6)	9 (3)
Arthralgia	17 (6)	10 (3)
Sneezing	17 (6)	8 (3)
Sore throat	17 (6)	10 (3)
Chest discomfort	13 (4)	9 (3)
Diarrhoea	13 (4)	4 (1)
Abdominal distention	11 (4)	6 (2)
Palpitations	11 (4)	5 (2)
Insomnia	11 (4)	5 (2)
Phlegm	10 (3)	5 (2)
Nausea	9 (3)	5 (2)
Cough	8 (3)	4 (1)
Abdominal pain	7 (2)	4 (1)
Constipation	6 (2)	4 (1)
Body itching	5 (2)	2 (1)
Flushing of the face	4 (1)	3 (1)
Skin rash	3 (1)	1 (0)
Chest pain	3 (1)	0 (0)
Enlarged lymph nodes	3 (1)	0 (0)
Face swelling	2 (1)	0 (0)
Arm or leg swelling	1 (0)	1 (0)
Muscle spasms	1 (0)	1 (0)
Confusion	1 (0)	1 (0)

Dyspnea	1 (0)	0 (0)
Nosebleeds	0 (0)	0 (0)
Ageusia	0 (0)	0 (0)
Anosmia	0 (0)	0 (0)
Conjunctivitis	0 (0)	0 (0)
Vomiting	0 (0)	0 (0)
Facial drooping/ weakness	0 (0)	0 (0)
Loss of consciousness	0 (0)	0 (0)
Seizure	0 (0)	0 (0)

---

484

485







486

487


488 **Supplementary Table 1. Antibody levels measured by ELISA, sVNT and PRNT against**  
 489 **ancestral SARS-CoV-2 virus and the Omicron variant at Day 0 and 28 after third-dose**  
 490 **BNT162b2 vaccination, in 20 randomly selected participants who previously received two**  
 491 **doses of inactivated COVID-19 vaccine. D0: Day 0 (baseline); D28: Day 28 (post-**  
 492 **vaccination); ELISA: enzyme-linked immunosorbent assay; sVNT: surrogate virus neutralisation**  
 493 **test; PRNT: plaque reduction neutralisation test; PRNT<sub>50</sub>: 50% plaque reduction neutralization**  
 494 **titer; PRNT<sub>90</sub>: 90% plaque reduction neutralization titer**  
 495

	Ancestral SARS-CoV-2 virus								Omicron variant			
	ELISA Spike RBD IgG (OD <sub>450</sub> )		sVNT % inhibition (%)		PRNT <sub>50</sub> titer		PRNT <sub>90</sub> titer		PRNT <sub>50</sub> titer		PRNT <sub>90</sub> titer	
	D0	D28	D0	D28	D0	D28	D0	D28	D0	D28	D0	D28
1	0.2	1.7	20	94	<10	160	<10	40	<10	<10	<10	<10
2	0.1	2.6	0	97	<10	≥320	<10	≥320	<10	10	<10	<10
3	1.2	1.9	6	97	<10	≥320	<10	160	<10	20	<10	10
4	0.1	1.9	3	97	<10	≥320	<10	160	<10	40	<10	10
5	0.2	1.9	14	97	<10	≥320	<10	160	<10	80	<10	40
6	0.3	2.0	30	97	<10	≥320	<10	≥320	<10	80	<10	20
7	0.1	1.8	0	96	10	160	<10	40	<10	20	<10	10
8	0.2	2.7	23	97	10	≥320	<10	≥320	<10	20	<10	10
9	0.7	1.5	42	97	10	≥320	<10	≥320	<10	40	<10	10
10	0.2	1.9	0	97	10	≥320	<10	≥320	<10	40	<10	10
11	0.5	1.7	48	91	10	≥320	<10	≥320	<10	160	<10	40
12	0.2	2.1	19	98	10	≥320	<10	80	<10	≥320	<10	160
13	0.2	1.8	23	97	20	≥320	<10	160	<10	20	<10	<10
14	0.2	1.7	28	97	20	≥320	<10	160	<10	40	<10	10
15	0.2	1.9	6	97	20	≥320	<10	≥320	<10	≥320	<10	80
16	0.2	2.0	5	97	20	≥320	<10	≥320	10	40	<10	20
17	0.4	1.7	37	97	40	≥320	10	≥320	<10	80	<10	20
18	0.2	2.8	29	97	40	≥320	10	≥320	<10	80	<10	20
19	0.7	2.0	44	97	40	≥320	10	≥320	<10	160	<10	40
20	0.2	1.9	36	97	40	≥320	10	≥320	<10	≥320	<10	160


496  
 497  
 498  
 499


**A****Ancestral ELISA****B****Ancestral sVNT****C****Ancestral PRNT<sub>50</sub>****D****Ancestral PRNT<sub>90</sub>****E****Omicron PRNT<sub>50</sub>****F****Omicron PRNT<sub>90</sub>**


# Solicited local reactions



# Solicited systemic reactions\*





**A****B**